Ligand to Report Second Quarter Results on August 1st
Ligand Announces Positive Preclinical Data for Glucagon Program in Model of Type 1 Diabetes
Ligand Raises Ownership Limit for BVF Partners to 25% of Shares Outstanding
Ligand Provides New Corporate Presentation at Investor Conference
Ligand to Present at Upcoming Investor Conferences
Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV
Ligand Reports First Quarter Financial Results
Ligand Acquires Financial Rights to More Than 15 Fully-Funded Development Programs from Selexis SA
Ligand Presents Preclinical Data on HepDirect™ Liver-Targeting Technology Platform at 2013 International Liver Congress (EASL) Annual Meeting
Ligand to Present at Upcoming Investor Conferences
Ligand to Report First Quarter Results on May 8th
Ligand Signs Global License Agreement with Spectrum Pharmaceuticals for Captisol-Enabled® Melphalan
Ligand Receives $1.4 Million Milestone Payment from Retrophin, Inc.
Ligand Reports Fourth Quarter and Full Year 2012 Financial Results
